Previous creatinine levels safely predict amantadine dose for influenza A outbreak control
JA Buxton, DM Skowronski, H Ng, et al
BACKGROUND:
Amantadine, an antiviral agent, is the only drug
currently approved in Canada for prophylaxis of influenza
A virus infection. To minimize side effects, the amantadine
dose is adjusted for age and estimated creatinine clearance
(CrCl) based on plasma creatinine (Cr) levels. As amantadine
is used more frequently for influenza A outbreak control
in care facilities for elderly people, physicians are
increasingly called on to prescribe it for residents
and to consider the necessity of requesting plasma Cr
levels.
OBJECTIVE:
To determine whether previous Cr levels are predictive
in estimating current CrCl and safe amantadine dose
determination.
DESIGN
AND SETTING: Residents' charts were reviewed in
two facilities in Vancouver, British Columbia. CrCl
estimated using previous or current Cr results, current
weight and age, as well as recommended amantadine doses
based on Canadian National Advisory Committee on Immunization
guidelines, were studied.
RESULTS:
165 charts with Cr results in March 1998 were included;
122 had results before March 1998, and 103 had Cr results
after March 1998. Pearson's correlation coefficient
for CrCl estimated from current and previous Cr values
was 0.929 for results less than six months previously,
0.974 for six to 12 months previously and 0.952 for
12 to 18 months previously. The same or a more conservative
dose of amantadine was predicted in 92% of cases when
using a Cr result taken within the previous year and
in 76% of cases when using a Cr result taken 12 to 18
months previously.
CONCLUSION:
In long term care facilities, Cr levels measured up
to 12 months previously can usually safely be used to
estimate CrCl. Using previous Cr results permits advance
preparation of doctor's orders for amantadine prophylaxis
and avoids repeating Cr testing on every resident when
an outbreak occurs, reducing related staff time and
cost.
|